MedTrace Logo

Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer

NCT04743752 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-04-26

No results posted yet for this study

Summary

This prospective, observational cohort study aims to explore the influence of obstructive sleep apnea(OSA) on the efficacy of PD-1-based immunotherapy in patients with non-small cell lung cancer(NSCLC). Patients who had no prior treatment for advanced NSCLC and are intended to receive PD-1/PD-L1 antibody will be recruited. According to sleep monitor results, participants will be divided into Group NSCLC and Group OSA+NSCLC. Primary outcome is the objective remission rate(ORR).

Conditions

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Jing Ma, MD · Peking University First Hospital

  • Guangfa Wang, MD · Peking University First Hospital

  • Yuan Cheng · Peking University First Hospital

  • Ligong Nie · Peking University First Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04743752 on ClinicalTrials.gov